Resmed Inc. (RMD) financials: revenue, earnings and cash flow
Fiscal 2017–2026 + TTM · from SEC filings · data as of November 13, 2026
Summary
Resmed’s revenue went from $2.1B in fiscal 2017 to $5.7B in fiscal 2026, growth of about 11.8% a year.
Net income in fiscal 2026 was $1.5B, a net margin of 26.9%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $5.7B and net income $1.6B.
Free cash flow was $1.6B in fiscal 2026 and positive in 10 of the 10 years shown.
The diluted share count rose 3% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.7B | $5.7B | $5.1B | $4.7B | $4.2B | $3.6B | $3.2B | $3.0B | $2.6B | $2.3B | $2.1B |
| Gross profit | $3.5B | $3.5B | $3.1B | $2.7B | $2.4B | $2.0B | $1.8B | $1.7B | $1.5B | $1.3B | $1.2B |
| Operating income | $1.9B | $1.9B | $1.7B | $1.3B | $1.1B | $1.0B | $904M | $810M | $579M | $542M | $426M |
| Net income | $1.6B | $1.5B | $1.4B | $1.0B | $898M | $779M | $475M | $622M | $405M | $316M | $342M |
| EPS (diluted) | $10.98 | $10.43 | $9.51 | $6.92 | $6.09 | $5.30 | $3.24 | $4.27 | $2.80 | $2.19 | $2.40 |
| R&D | $394M | $378M | $331M | $308M | $288M | $254M | $225M | $202M | $181M | $155M | $144M |
| Revenue growth | — | +9.8% | +9.8% | +10.9% | +18.0% | +11.9% | +8.1% | +13.4% | +11.4% | +13.2% | +12.4% |
Cash flow
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.8B | $1.8B | $1.8B | $1.4B | $693M | $351M | $737M | $802M | $459M | $505M | $414M |
| Capital spending | -$162M | -$156M | -$90M | -$99M | -$120M | -$135M | -$103M | -$95M | -$69M | -$63M | -$62M |
| Free cash flow | $1.6B | $1.6B | $1.7B | $1.3B | $574M | $216M | $634M | $707M | $390M | $442M | $352M |
| Dividends paid | $357M | $350M | $311M | $282M | $258M | $245M | $227M | $225M | $212M | $199M | $186M |
| Buybacks | $1.5B | $700M | $300M | $150M | $0 | $0 | — | — | $23M | $54M | — |
| Stock-based pay | $113M | $104M | $92M | $80M | $71M | $65M | $64M | $58M | $52M | $48M | $46M |
Balance sheet
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $1.5B | $1.2B | $238M | $228M | $274M | $295M | $463M | $147M | $189M | $822M |
| Debt | — | $826M | $852M | $874M | $1.6B | $918M | $794M | $1.3B | $1.3B | $281M | $1.1B |
| Equity | — | $6.6B | $6.0B | $4.9B | $4.1B | $3.4B | $2.9B | $2.5B | $2.1B | $2.1B | $2.0B |
| Total assets | — | $9.0B | $8.2B | $6.9B | $6.8B | $5.1B | $4.7B | $4.6B | $4.1B | $3.1B | $3.5B |
| Shares (diluted) | 143M | 146M | 147M | 148M | 147M | 147M | 146M | 146M | 144M | 144M | 142M |
Margins and returns
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 61.1% | 61.1% | 59.4% | 56.7% | 55.8% | 56.6% | 57.5% | 58.1% | 57.3% | 57.0% | 58.1% |
| Operating margin | 33.0% | 33.4% | 32.8% | 28.2% | 26.8% | 28.0% | 28.3% | 27.4% | 22.2% | 23.2% | 20.6% |
| Net margin | 27.8% | 26.9% | 27.2% | 21.8% | 21.2% | 21.8% | 14.8% | 21.0% | 15.5% | 13.5% | 16.6% |
| FCF margin | 28.1% | 29.2% | 32.3% | 27.8% | 13.6% | 6.0% | 19.8% | 23.9% | 15.0% | 18.9% | 17.0% |
| ROIC | — | 20.2% | 20.6% | 18.6% | 16.2% | 19.0% | 13.2% | 18.1% | 13.5% | 14.0% | 11.5% |
| ROE | — | 23.1% | 23.5% | 21.0% | 21.7% | 23.2% | 16.4% | 24.9% | 19.5% | 15.3% | 17.5% |
Frequently asked questions
What is Resmed’s annual revenue?
$5.7B in fiscal 2026 and $5.7B over the twelve months to September 30, 2026.
How much profit does Resmed make?
Net income was $1.5B in fiscal 2026 (net margin 26.9%).
Is Resmed’s revenue growing?
Yes: revenue rose 9.9% in fiscal 2026 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.